Literature DB >> 15800902

Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.

G Wei Xu1, Joe S Mymryk, J Gregory Cairncross.   

Abstract

Pifithrin-alpha (PFTalpha) is a small molecule inhibitor of p53. By reversibly blocking apoptosis in response to DNA damage, PFTalpha protects normal cells from lethal doses of gamma-radiation (Komarov et al., Science, 1999;285:1733-7). We examined the effect of PFTalpha on the chemosensitivity of a human cancer in which cell cycle arrest, not apoptosis, is the principle cellular consequence of p53 activation. This was of interest because E6 silencing of p53 sensitizes U87MG astrocytic glioma cells to BCNU and temozolomide (TMZ), cytotoxic drugs that are modestly helpful in the treatment of aggressive astrocytic gliomas. We observed that exposure of U87MG cells to PFTalpha before cytotoxic chemotherapy attenuated p53-mediated induction of p21WAF1 protein levels, sensitizing U87MG cells to BCNU and TMZ. Sensitization of U87MG cells was associated with G1 arrest, delayed entry into S-phase and decreased repair of DNA damage by BCNU. Our findings suggest that in addition to protecting normal cells from the toxic effects of radiation and chemotherapy, small molecule inhibitors of p53, like PFTalpha, might play a role in clinical oncology by sensitizing certain resistant cancers to cytotoxic chemotherapies. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800902     DOI: 10.1002/ijc.21071

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  A rapid survival assay to measure drug-induced cytotoxicity and cell cycle effects.

Authors:  Chandni Valiathan; Jose L McFaline; Leona D Samson
Journal:  DNA Repair (Amst)       Date:  2011-11-30

2.  HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  Genglin Jin; Stephen Cook; Bo Cui; William C Chen; Stephen T Keir; Patrick Killela; Chunhui Di; Cathy A Payne; Simon G Gregory; Roger McLendon; Darell D Bigner; Hai Yan
Journal:  Neuro Oncol       Date:  2010-05-14       Impact factor: 12.300

3.  Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.

Authors:  Michael D Blough; Desiree C Beauchamp; Morgan R Westgate; John J Kelly; J Gregory Cairncross
Journal:  J Neurooncol       Date:  2010-07-01       Impact factor: 4.130

4.  Mutation of the gene encoding the circadian clock component PERIOD2 in oncogenic cells confers chemoresistance by up-regulating the Aldh3a1 gene.

Authors:  Chiharu Katamune; Satoru Koyanagi; Ken-Ichi Hashikawa; Naoki Kusunose; Takahiro Akamine; Naoya Matsunaga; Shigehiro Ohdo
Journal:  J Biol Chem       Date:  2018-11-14       Impact factor: 5.157

5.  Inhibition of p53 by adenovirus type 12 E1B-55K deregulates cell cycle control and sensitizes tumor cells to genotoxic agents.

Authors:  Qiang Li; Lisa Y Zhao; Zhi Zheng; Heng Yang; Aleixo Santiago; Daiqing Liao
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

6.  p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.

Authors:  Eduard B Dinca; Kan V Lu; Jann N Sarkaria; Russell O Pieper; Michael D Prados; Daphne A Haas-Kogan; Scott R Vandenberg; Mitchel S Berger; C David James
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.

Authors:  Xiang Wang; Jin-xiu Chen; Yan-hui Liu; Chao You; Qing Mao
Journal:  Neurol Sci       Date:  2012-12-08       Impact factor: 3.307

8.  Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells.

Authors:  Ella L Kim; Robin Wüstenberg; Anne Rübsam; Christoph Schmitz-Salue; Gabriele Warnecke; Eva-Maria Bücker; Nadine Pettkus; Daniel Speidel; Veit Rohde; Walter Schulz-Schaeffer; Wolfgang Deppert; Alf Giese
Journal:  Neuro Oncol       Date:  2010-01-27       Impact factor: 12.300

9.  2-(3-Aryl-2-propenoyl)-3-methylquinoxaline-1,4-dioxides: a novel cluster of tumor-specific cytotoxins which reverse multidrug resistance.

Authors:  Umashankar Das; Hari N Pati; Atulya K Panda; Erik De Clercq; Jan Balzarini; Joseph Molnár; Zoltán Baráth; Imre Ocsovszki; Masami Kawase; Li Zhou; Hiroshi Sakagami; Jonathan R Dimmock
Journal:  Bioorg Med Chem       Date:  2009-04-17       Impact factor: 3.641

10.  Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.

Authors:  Khong Bee Kang; Congju Zhu; Sook Kwin Yong; Qiuhan Gao; Meng Cheong Wong
Journal:  Mol Cancer       Date:  2009-08-25       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.